This is consistent with the fact that targeting RAS, BRAF, CRAF, BRAF+CRAF or MEK1+2 in HCT116 resulted in decreased proliferation in vitro and delayed tumor growth in vivo. This evidence concerns the gene MAP2K1 and neoplasm.